IO Biotech Inc (IOBT) Company Sales

IO Biotech, Inc. (IOBT) is implementing ESG principles by minimizing chemical damage during the development of immuno-oncology agents. The company's sales volume trajectory clearly demonstrates revenue dynamics, with the current figure recorded at 0.00. The brand is valued in the US and Denmark for the development of metastasis vaccines, and the project's market success relies on the scientific superiority of the data over its counterparts.

iobiotech.com (IOBT): Company Revenue from 07/04/2022 to 04/18/2026

Analytical breakdowns for IO Biotech (IOBT)

- stock value and consensus price forecast:

Stock Quotes IO Biotech Inc.|IOBT - Price Target Chart

- market capitalization details:

Market Valuation IO Biotech, Inc.|IOBT - Real Price to Acquire Entire Company

- balance sheet equity data:

Book Value per Share IO Biotech|IOBT - Company Book Value|Capitalization to Book Value Ratio iobiotech.com|IOBT - Aggregate Company Assets

- debt obligations and liquidity statistics:

- net income and valuation ratios data:

IOBT - Company Net Income|Expected Net Income IO Biotech, Inc.|IOBT - P/E Multiple|Forward P/E Multiple iobiotech.com|IOBT - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio IO Biotech, Inc.|IOBT - Operating profit before deduction of amortization|Net earnings per one share for the last twelve months IO Biotech|IOBT - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months iobiotech.com|IOBT - Earnings per share growth in current year|Expected net earnings per share growth next year IO Biotech, Inc.

- sales volume and revenue indicators:

IOBT - Company Sales|Company Future Revenue IO Biotech Inc.|IOBT - P/S Multiple|Price-to-Projected Revenue Ratio IO Biotech, Inc.

General company analysis:IO Biotech Inc., IOBT

Sales for IO Biotech, Inc. (IOBT) capture the actual real-time cash inflow from product sales. This metric measures operational liquidity, revealing hidden imbalances within the capital structure. Analyzing the company's gross sales volume allows for an assessment of the business's current financial stability. This indicator is critical for IO Biotech, Inc. (IOBT), as the company is currently in a loss-making R&D stage. Revenue stability determines the developer's ability to fund vaccine clinical trials without the emergency procurement of external capital.

Key competitors